Solid Biosciences (NASDAQ:SLDB) Raised to “Strong-Buy” at Cantor Fitzgerald

Solid Biosciences (NASDAQ:SLDB) was upgraded by investment analysts at Cantor Fitzgerald to a “strong-buy” rating in a research note issued to investors on Tuesday,Zacks.com reports. Cantor Fitzgerald also issued estimates for Solid Biosciences’ FY2025 earnings at ($1.60) EPS.

Several other research analysts have also recently issued reports on the company. Chardan Capital reissued a “buy” rating and issued a $16.00 target price on shares of Solid Biosciences in a research report on Friday, March 7th. JPMorgan Chase & Co. lowered their price objective on shares of Solid Biosciences from $12.00 to $11.00 and set an “overweight” rating on the stock in a research note on Thursday, March 13th. Finally, HC Wainwright raised their price objective on shares of Solid Biosciences from $16.00 to $20.00 and gave the stock a “buy” rating in a report on Monday, March 10th. Eight investment analysts have rated the stock with a buy rating and five have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $15.67.

Solid Biosciences Price Performance

SLDB stock opened at $2.55 on Tuesday. Solid Biosciences has a 1 year low of $2.45 and a 1 year high of $10.46. The company has a market cap of $197.63 million, a P/E ratio of -0.84 and a beta of 2.32. The stock’s fifty day moving average price is $3.63 and its 200-day moving average price is $4.26.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. CWM LLC raised its stake in Solid Biosciences by 15,188.5% during the 1st quarter. CWM LLC now owns 7,950 shares of the company’s stock worth $29,000 after acquiring an additional 7,898 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in shares of Solid Biosciences in the fourth quarter worth approximately $34,000. Corton Capital Inc. purchased a new stake in shares of Solid Biosciences in the fourth quarter worth $41,000. Ground Swell Capital LLC bought a new stake in shares of Solid Biosciences during the 1st quarter valued at $42,000. Finally, Invesco Ltd. bought a new stake in shares of Solid Biosciences during the 4th quarter valued at $49,000. 81.46% of the stock is owned by hedge funds and other institutional investors.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.